Naltrexone Completed Phase 2 Trials for Borderline Personality Disorder (BPD) / Dissociation Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01133301Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder